In addition, a comprehensive analysis of tumour immunity for cancer immunotherapy has also identified SPAG5 as a potential candidate for future vaccine development in multiple cancers, in which the median SPAG5 expression in these cancers is at least threefold over normal [15]. This evidence concerns the gene SPAG5 and neoplasm.